{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:30:26Z","timestamp":1791127826718,"version":"4.1.0"},"reference-count":26,"publisher":"Oncology Nursing Society (ONS)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2005,6,1]]},"DOI":"10.1188\/05.cjon.332-338","type":"journal-article","created":{"date-parts":[[2006,2,20]],"date-time":"2006-02-20T09:09:37Z","timestamp":1140426577000},"page":"332-338","source":"Crossref","is-referenced-by-count":38,"title":["Cetuximab: Adverse Event Profi le and Recommendations for Toxicity Management"],"prefix":"10.1188","volume":"9","author":[{"given":"Melodie","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1302","published-online":{"date-parts":[[2007,2,8]]},"reference":[{"key":"E00001","doi-asserted-by":"crossref","unstructured":"Bartlett, J.M., Langdon, S.P., Simpson, B.J., Stewart, M., Katsaros, D., Sismondi, P., et al. (1996). The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. British Journal of Cancer<\/i>, 73<\/i>, 301-306.","DOI":"10.1038\/bjc.1996.53"},{"key":"E00002","unstructured":"Baselga, J. (2000). New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal<\/i>, 1<\/i>, 12-21."},{"key":"E00003","doi-asserted-by":"crossref","unstructured":"Baselga, J. (2002). Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist<\/i>, 7<\/i>(Suppl. 4), 2-8.","DOI":"10.1634\/theoncologist.7-suppl_4-2"},{"key":"E00004","unstructured":"Bos, M., Mendelsohn, J., Bowden, C., Pfister, D., Cooper, M.R., Cohen, R., et al. (1996). Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors [Abstract 1381]. Proceedings of the American Society of Clinical Oncology<\/i>, 15<\/i>, 443."},{"key":"E00005","unstructured":"Bucci, B., D'Agnano, I., Botti, C., Mottolese, M., Carico, E., Zupi, G., et al. (1997). EGF-R expression in ductal breast cancer: Proliferation and prognostic implications. Anticancer Research<\/i>, 17<\/i>, 769-774."},{"key":"E00006","unstructured":"Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., et al. (2003). Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) [Abstract 1012]. Proceedings of the American Society of Clinical Oncology<\/i>, 22<\/i>, 252."},{"key":"E00007","unstructured":"Falcey, J., Pfister, D., Cohen, R., Cooper, M., Bowden, C., Burtness, B., et al. (1997). A study of anti-epidermal growth factor receptor (EGFr) monoclonal antibody C225 and cisplatin in patients (pts) with head and neck or lung carcinomas [Abstract 1364]. Proceedings of the American Society of Clinical Oncology<\/i>, 16<\/i>, 383a."},{"key":"E00008","doi-asserted-by":"crossref","unstructured":"Hollywood, E. (2002). Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225. Seminars in Oncology Nursing<\/i>, 18<\/i>(2, Suppl. 2), 30-35.","DOI":"10.1053\/sonu.2002.33070"},{"key":"E00009","unstructured":"ImClone Systems Incorporated. (2004). Erbitux\u2122 (cetuximab) full prescribing information. New York, NY: Author."},{"key":"E00010","unstructured":"Klijn, J.G., Berns, P.M., Schmitz, P.I., & Foekens, J.A. (1992). The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocrine Reviews<\/i>, 13<\/i>, 3-17."},{"key":"E00011","unstructured":"Mendelsohn, J. (2000). Blockade of receptors for growth factors: An anticancer therapy-The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clinical Cancer Research<\/i>, 6<\/i>, 747-753."},{"key":"E00012","doi-asserted-by":"crossref","unstructured":"Messa, C., Russo, F., Caruso, M.G., & DiLeo, A. (1998). EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncologica<\/i>, 37<\/i>, 285-289.","DOI":"10.1080\/028418698429595"},{"key":"E00013","unstructured":"Ream, M.A., & Tunison, D. (1998). Hypersensitivity reactions. In J.M. Yasko (Ed.), Nursing management of symptoms associated with chemotherapy<\/i> (pp. 213-224). Bala Cynwyd, PA: Meniscus Health Care."},{"key":"E00014","doi-asserted-by":"crossref","unstructured":"Riddle, J., Lee, P., & Purdom, M. (2002). The epidermal growth factor receptor as a novel target for cancer therapy: Case studies and clinical implications. Seminars in Oncology Nursing<\/i>, 18<\/i>(4, Suppl. 4), 11-19.","DOI":"10.1053\/sonu.2002.37407"},{"key":"E00015","doi-asserted-by":"crossref","unstructured":"Rubin Grandis, J., Melhem, M.F., Barnes, E.L., & Tweardy, D.J. (1996). Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer<\/i>, 78<\/i>, 1284-1292.","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1284::AID-CNCR17>3.0.CO;2-X"},{"key":"E00016","unstructured":"Rusch, V., Klimstra, D., Venkatraman, E., Pisters, P.W.T., Langenfeld, J., & Dmitrovsky, E. (1997). Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clinical Cancer Research<\/i>, 3<\/i>, 515-522."},{"key":"E00017","unstructured":"RxMed. (2005). Atropine sulfate injection USP. Retrieved May 16, 2005, from http:\/\/www.rxmed.com\/b.main\/b2.pharmaceutical\/b2.prescribe.html<\/a>"},{"key":"E00018","doi-asserted-by":"crossref","unstructured":"Salomon, D.S., Brandt, R., Ciardiello, F., & Normanno, N. (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology\/Hematology<\/i>, 19<\/i>, 183-232.","DOI":"10.1016\/1040-8428(94)00144-I"},{"key":"E00019","unstructured":"Saltz, L., Kies, M., Abbruzzese, J.L., Azarnia, N., & Needle, M. (2003). The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies [Abstract 817]. Proceedings of the American Society of Clinical Oncology<\/i>, 22<\/i>, 204."},{"key":"E00020","unstructured":"Saltz, L., Rubin, M., Hochster, H., Tchekmeydian, N.S., Waksal, H., Needle, M., et al. (2001). Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [Abstract 7]. Proceedings of the American Society of Clinical Oncology<\/i>, 20<\/i>, 3a."},{"key":"E00021","doi-asserted-by":"crossref","unstructured":"Saltz, L.B., Meropol, N.J., Loehrer, P.J., Sr., Needle, M.N., Kopit, J., & Mayer, R.J. (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. Journal of Clinical Oncology<\/i>, 22<\/i>, 1201-1208.","DOI":"10.1200\/JCO.2004.10.182"},{"key":"E00022","doi-asserted-by":"crossref","unstructured":"Waxman, E.S., & Herbst, R.S. (2002). The role of the epidermal growth factor receptor in the treatment of colorectal carcinoma. Seminars in Oncology Nursing<\/i>, 18<\/i>(2, Suppl. 2), 20-29.","DOI":"10.1053\/sonu.2002.33072"},{"key":"E00023","doi-asserted-by":"crossref","unstructured":"Wood, L.S. (2002). Rationale for the epidermal growth factor receptor as a target for cancer therapy. Seminars in Oncology Nursing<\/i>, 18<\/i>(4, Suppl. 4), 3-10.","DOI":"10.1053\/sonu.2002.37406"},{"key":"E00024","doi-asserted-by":"crossref","unstructured":"Woodburn, J.R. (1999). The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacology and Therapeutics<\/i>, 82<\/i>, 241-250.","DOI":"10.1016\/S0163-7258(98)00045-X"},{"key":"E00025","unstructured":"Yamanaka, Y., Friess, H., Kobrin, M.S., Buchler, M., Beger, H.G., & Korc, M. (1993). Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Research<\/i>, 13<\/i>, 565-569."},{"key":"E00026","doi-asserted-by":"crossref","unstructured":"Zanotti, K.M., & Markman, M. (2001). Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Safety<\/i>, 24<\/i>, 767-779.","DOI":"10.2165\/00002018-200124100-00005"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/72808G73H181L853.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:08Z","timestamp":1763754728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/9\/3\/cetuximab-adverse-event-profile-and-recommendations-toxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,1]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6,1]]}},"alternative-id":["72808G73H181L853"],"URL":"https:\/\/doi.org\/10.1188\/05.cjon.332-338","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,1]]}}}